These results are important as they indicate that targeting Cer biosynthetic pathways for alteration in levels of specific miRNAs may provide significant therapeutic benefits in relapsing remitting MS patients. This evidence concerns the gene CBLN1 and relapsing-remitting multiple sclerosis.